Most owners describe a pharmacy sale as selling a business. Legally and commercially it is closer to transferring a permission to trade at a particular address, together with the shop that happens to sit there. The distinction explains why pharmacy transactions fail in ways that surprise their owners, and why two pharmacies with identical accounts can be worth very different amounts.
Two features drive everything. First, in much of Europe the law decides who may buy: ownership is restricted to pharmacists, which removes most of the buyer universe before commercial negotiation begins. Second, the licence is effectively attached to premises the seller usually does not own. A landlord who declines to extend a lease, or sells the building to someone with other plans, can cut the value of a profitable pharmacy faster than any trading problem.
This article sets out who is legally permitted to buy, what pharmacies actually sell for, why the lease is part of the asset rather than a cost line, and what to fix before going to market.
The buyer pool for a European pharmacy is defined by statute before it is defined by price.
The position was settled at EU level in 2009, when the Court of Justice ruled on German and Italian rules restricting pharmacy ownership. The Court accepted that such restrictions limit freedom of establishment and the free movement of capital, but held that they can be justified where medicinal products are concerned: national legislation preventing persons who are not pharmacists from owning and operating pharmacies is compatible with EU law.
Member states have used that freedom differently, and the split matters enormously to a seller.
In Germany the owner must be a pharmacist, may hold a main pharmacy plus up to three branches, must personally manage the main one, must employ a responsible pharmacist at each branch, and must keep the branches in the same or a neighbouring district. Corporate ownership is not permitted in France, Germany, Greece, Italy or Spain, and chains in the ordinary sense do not exist in France or Spain. The German pharmacists' association notes that most EU pharmacies sit in member states applying restrictions similar to Germany's, and that fewer than half operate in states without such requirements.
Elsewhere — the United Kingdom, the Netherlands, Ireland, the Nordic countries — corporate and chain ownership is permitted, and consolidated groups and wholesaler-affiliated chains are active acquirers.
For a seller the consequence is direct. In a restricted market the realistic buyer is an individual pharmacist, financing the purchase personally: more price-sensitive, slower, dependent on bank credit, and far more affected by the lease position than a corporate acquirer. In a liberalised market the pool includes groups that underwrite on EBITDA and move quickly. Knowing which market you are in should shape the whole process design.
Published pharmacy benchmarks should be treated with more caution than in most sectors, because they mix markets with entirely different regulatory and reimbursement systems.
The broadly quoted range for independent community pharmacies sits in low-to-mid single digits of adjusted EBITDA — commonly cited as roughly 3x to 6x, with the middle of that band more typical for a single site. Percentage-of-turnover rules of thumb still circulate in some markets, particularly the UK, where smaller pharmacies are often discussed at a share of annual turnover rather than a profit multiple. Both conventions can be reconciled, but only after the earnings have been normalised.
Normalisation matters more here than the multiple. A pharmacy's reported profit typically needs adjusting for the owner-pharmacist's own professional work, since a buyer who does not intend to stand behind the counter must employ a responsible pharmacist at market rates. It also needs adjusting for any rent paid to a related party, for stock valuation policy, and for one-off wholesaler rebates or bonus schemes that will not recur on the same terms. At Conclave Partners we would rather spend the first two weeks of a pharmacy mandate rebuilding the earnings than debating a multiple that will be applied to the wrong number.
Revenue multiples deserve particular scepticism in dispensing businesses. Turnover is dominated by reimbursed medicines whose margin is set by the state, so two pharmacies with the same revenue can have materially different gross profit depending on generic mix, dispensing fees, service income and the share of higher-margin over-the-counter and retail sales.
In most European systems a pharmacy licence authorises dispensing at a specified location, and new licences are rationed by demographic and geographic criteria rather than granted on demand.
France applies population quotas: broadly 2,500 inhabitants for the first licence in a commune and 4,500 for each subsequent one. Spain sets density rules — in rural pharmaceutical areas one pharmacy per 2,000 registered inhabitants, with a further one possible where that proportion is exceeded by 1,500 and the population has grown over the preceding five years. Minimum distance requirements from an existing pharmacy are common, frequently around 250 metres. In Finland, Denmark and Luxembourg openings require government authorisation, with number and siting set by demographic and geographic criteria. Germany is the exception: it imposes no such test, which is why its restriction operates on who may own rather than where.
These rules are why a pharmacy's location is not merely convenient — it is protected. A buyer acquires catchment that a competitor cannot replicate across the road. The same rules explain the vulnerability: if the pharmacy cannot continue at that address, what is at risk is the protected position, not just the fit-out.
This is where profitable pharmacies lose value quietly, and it is the item most often addressed too late.
Most community pharmacies are tenants. The lease therefore carries part of the licence's economic value, and buyers price it that way. A pharmacy with fifteen years of secure occupation is a different asset from the same pharmacy with three years remaining and a landlord who has not committed to renew, even though the profit and loss accounts are identical.
Four situations recur.
The first is a short residual term. Buyers, and the banks financing them, generally want a horizon long enough to amortise the purchase. Where the remaining term is short and renewal is uncertain, the response is rarely a modest discount — it is a refusal to proceed, or an offer restructured so that most of the risk sits with the seller.
The second is a change of landlord during the process. When a building is sold to an investor or developer mid-transaction, the assumptions behind the lease change. A new owner may want a higher rent, a shorter term, or vacant possession for redevelopment. Sellers frequently discover this only when the buyer's solicitor requests landlord consent.
The third is the assignment clause. Many leases require landlord consent to assign, sometimes with conditions on the incoming tenant's covenant strength. An individual pharmacist with a new company and a bank loan is exactly the tenant a cautious landlord scrutinises — and in restricted markets that is the only buyer available.
The fourth is a rent review falling due around completion. An open review transfers an unquantified cost to the buyer, who will either price the worst case or ask the seller to carry it.
Where the seller owns the premises personally, the position is better but needs structuring. Selling the business alone and granting a documented lease at market rent widens the buyer pool, because most pharmacist buyers cannot fund both. A below-market intercompany rent inflates the EBITDA the buyer is underwriting and will be normalised away; an above-market one depresses it. In our experience at Conclave Partners, settling the property question before launch is worth more to a pharmacy seller than any tactic applied afterwards.
A buyer is underwriting the durability of a regulated margin, not a commercial one.
Present the composition of gross profit explicitly: reimbursed prescription margin, dispensing and service fees, over-the-counter and retail sales, and professional services. That last category has grown across Europe — the Pharmaceutical Group of the European Union, representing around 500,000 community pharmacists and some 200,000 pharmacies across 33 countries, has mapped 47 distinct pharmacy services, with countries implementing 26 on average. Buyers regard service income well because it is less exposed to medicine price deflation, but it must be shown separately and evidenced by contract.
Buyers also examine wholesaler arrangements closely. Discount and rebate structures, any tie to a single wholesaler, buying-group membership and whether terms are personal to the current owner all feed into the sustainable margin. Terms that do not transfer are a permanent deduction, not a negotiating point.
Pharmacy revenue often depends on a small number of prescribing sources: an adjacent medical centre, one or two prescribers, a care home contract, a dosette or compliance packaging service.
Buyers treat this like customer concentration anywhere else, with one aggravation: the relationship is usually informal and cannot be assigned. A single-doctor practice that relocates or retires can move a large share of dispensing volume within weeks. Where a care home or institutional contract is material, its written terms, duration and notice period become directly relevant to price, and an unwritten arrangement is discounted heavily.
The practical answer is documentation and diversification, plus honest presentation of the concentration that does exist. Concealing it does not work: buyers reconstruct it from the dispensing data.
Stock is a real number in a pharmacy sale and usually valued separately from goodwill, at cost, on a count taken at completion. Slow-moving, short-dated and obsolete lines are excluded or written down. An owner who has allowed stock to drift upward is not banking value — they are creating an argument.
Staffing is the operational equivalent of the ownership rule. A responsible pharmacist must be present to dispense, so a buyer who will not stand behind the counter must recruit one, and that cost belongs in the normalised earnings. Long-tenured staff support both continuity of service and the relationships that bring patients back.
Compliance diligence is heavier than in ordinary retail: registration and inspection history, controlled drugs registers and storage, temperature logs, standard operating procedures, professional indemnity and patient records under GDPR. None of it creates value; all of it consumes time and leverage if assembled reactively.
In restricted markets the buyer is a pharmacist — often an employed pharmacist buying their first business, sometimes an owner adding a branch within the legal limits. They are motivated and knowledgeable but constrained by financing, and bank appetite turns on the lease term, the licence position and the normalised earnings.
In liberalised markets, groups and wholesaler-affiliated chains buy for network density, purchasing leverage and service scale. They pay on EBITDA, complete more reliably, and are untroubled by the personal financing constraints that limit an individual buyer.
A third route, available almost everywhere, is a sale to a neighbouring owner who can absorb the volume — a buyer who may pay well precisely because the acquisition removes a competitor from a protected catchment. Identifying which routes a specific pharmacy realistically has, before any materials are written, is most of what an adviser contributes, and it is where Conclave Partners spends the first weeks of a pharmacy mandate.
Deal with the lease first. Extend the term, obtain a documented renewal option, or at minimum establish in writing what the landlord will and will not agree to on assignment. If the building has recently changed hands, find out what the new owner intends before a buyer does.
Rebuild the earnings honestly. Include the market cost of a responsible pharmacist if you work in the pharmacy yourself, a market rent if the premises are related-party, and remove wholesaler bonuses or rebates that will not continue on the same terms. Adjustments a buyer can verify are accepted; adjustments supported only by the owner's word cause the buyer to discount the entire earnings figure.
Present the gross profit by stream — prescription margin, fees, services, retail — for at least twenty-four months, reconciled to the accounts.
Document prescription sources and any institutional contracts, and put verbal arrangements into writing before the process starts rather than during it.
Clean the stock. Clear short-dated and slow-moving lines and adopt a consistent valuation policy, so the completion stocktake produces a number close to what the accounts imply.
Get the compliance file in order: inspection reports, controlled drugs records, SOPs, staff registrations and the data protection position. Sellers who ask Conclave Partners where to begin are pointed at the lease and the normalised earnings before anything else, because those two items determine whether a bank will fund a buyer at all.
A prepared pharmacy typically takes six to nine months from launch to completion, and the timetable is set by two external parties rather than by the negotiation itself: the landlord, whose consent to assignment is required, and the regulator, where a change of ownership needs notification or approval.
Buyer financing is the third common delay. Where the purchaser is an individual pharmacist, the bank runs its own review of the lease and the earnings, and any weakness found there returns as a request to cut the price or defer part of it.
Confidentiality deserves attention. Pharmacy staff are few and hard to replace, and prescribing relationships are personal; a leak during diligence can damage the trading position the buyer is paying for.
Independent community pharmacies are commonly discussed at roughly 3x to 6x adjusted EBITDA, and in some markets, notably the UK, at a percentage of annual turnover instead. Both conventions mean something only after earnings are normalised for a responsible pharmacist's salary, related-party rent and non-recurring wholesaler income. Position within the range is driven by lease security, licence position, margin mix and prescription concentration.
Not in much of Europe. The Court of Justice of the European Union confirmed in 2009 that member states may prevent non-pharmacists from owning and operating pharmacies, and France, Germany, Greece, Italy and Spain do not permit corporate ownership. Germany additionally limits a pharmacist to one main pharmacy and three branches. In the UK, Ireland, the Netherlands and the Nordics, corporate and chain buyers are permitted.
The licence authorises dispensing at a particular location and is subject to national change-of-ownership procedure, usually notification or approval rather than free transfer. Because new licences are rationed by population and distance criteria in many countries, the existing authorisation at an established address is often the most valuable element of the transaction.
The value falls sharply, because the buyer is acquiring the right to dispense at that address. In practice a short unrenewed lease either deters buyers outright or converts a large part of the price into deferred or contingent consideration. This is the reason to settle the lease position before going to market rather than during due diligence.
Usually yes, if you own the premises. Most pharmacist buyers cannot finance both, so retaining the property and granting a market-rent lease widens the buyer pool and leaves you an income-producing asset. The lease must be properly documented, because an artificial rent distorts the earnings the buyer is underwriting.
Roughly six to nine months from launch to completion for a prepared business. Landlord consent, regulatory change-of-ownership procedure and the buyer's bank financing are the three items most likely to extend that, and all three are easier when the lease and the normalised accounts were prepared in advance.
Ildar Zakirov — Conclave Partners ildar@conclavepartners.com
Sergi Kosiakof — Conclave Partners sergi@conclavepartners.com